1	Islet	Islet	B-NP	NN	O	3	NMOD	-1
2	endothelial	endothelial	I-NP	JJ	O	3	NMOD	-1
3	activation	activation	I-NP	NN	O	8	NMOD	17	activation
4	and	and	O	CC	O	8	NMOD	-1
5	oxidative	oxidative	B-NP	JJ	O	8	NMOD	-1
6	stress	stress	I-NP	NN	O	8	NMOD	-1
7	gene	gene	I-NP	NN	O	8	NMOD	-1
8	expression	expression	I-NP	NN	O	9	SUB	0
9	is	be	B-VP	VBZ	O	0	ROOT	-1
10	reduced	reduce	I-VP	VBN	O	9	VC	18	reduced
11	by	by	B-PP	IN	O	10	VMOD	-1
12	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	13	NMOD	-1
13	treatment	treatment	I-NP	NN	O	11	PMOD	19	treatment
14	in	in	B-PP	IN	O	13	NMOD	-1
15	the	the	B-NP	DT	O	20	NMOD	-1
16	type	type	I-NP	NN	O	20	NMOD	-1
17	2	2	I-NP	CD	O	20	NMOD	-1
18	diabetic	diabetic	I-NP	JJ	O	20	NMOD	-1
19	GK	GK	I-NP	NN	O	20	NMOD	-1
20	rat	rat	I-NP	NN	O	14	PMOD	-1
21	.	.	O	.	O	9	P	-1

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Inflammation	Inflammation	B-NP	NN	O	7	SUB	-1
4	followed	follow	B-VP	VBN	O	3	NMOD	-1
5	by	by	B-PP	IN	O	4	VMOD	-1
6	fibrosis	fibrosis	B-NP	NN	O	5	PMOD	-1
7	is	be	B-VP	VBZ	O	1	NMOD	-1
8	a	a	B-NP	DT	O	9	NMOD	-1
9	component	component	I-NP	NN	O	7	PRD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	islet	islet	B-NP	NN	O	12	NMOD	-1
12	dysfunction	dysfunction	I-NP	NN	O	10	PMOD	6	dysfunction
13	in	in	B-PP	IN	O	7	VMOD	-1
14	both	both	O	CC	O	20	NMOD	-1
15	rodent	rodent	B-NP	NN	O	20	NMOD	-1
16	and	and	O	CC	O	20	NMOD	-1
17	human	human	B-NP	JJ	O	18	NMOD	-1
18	type	type	I-NP	NN	O	20	NMOD	-1
19	2	2	B-NP	CD	O	18	NMOD	-1
20	diabetes	diabete	I-NP	NNS	O	13	PMOD	-1
21	.	.	O	.	O	7	P	-1

1	Because	Because	B-SBAR	IN	O	11	VMOD	-1
2	islet	islet	B-NP	NN	O	3	NMOD	-1
3	inflammation	inflammation	I-NP	NN	O	4	SUB	-1
4	may	may	B-VP	MD	O	1	SBAR	-1
5	originate	originate	I-VP	VB	O	4	VC	0
6	from	from	B-PP	IN	O	5	VMOD	-1
7	endothelial	endothelial	B-NP	JJ	B-cell_type	8	NMOD	-1
8	cells	cell	I-NP	NNS	I-cell_type	6	PMOD	-1
9	,	,	O	,	O	11	P	-1
10	we	we	B-NP	PRP	O	11	SUB	-1
11	assessed	assess	B-VP	VBD	O	0	ROOT	-1
12	the	the	B-NP	DT	O	13	NMOD	-1
13	expression	expression	I-NP	NN	O	11	OBJ	0
14	of	of	B-PP	IN	O	13	NMOD	-1
15	selected	select	B-NP	VBN	O	16	NMOD	-1
16	genes	gene	I-NP	NNS	O	14	PMOD	-1
17	involved	involve	B-VP	VBN	O	16	NMOD	0
18	in	in	B-PP	IN	O	17	VMOD	-1
19	endothelial	endothelial	B-NP	JJ	B-cell_type	21	NMOD	-1
20	cell	cell	I-NP	NN	I-cell_type	21	NMOD	-1
21	activation	activation	I-NP	NN	O	18	PMOD	17	activation
22	in	in	B-PP	IN	O	21	NMOD	-1
23	islets	islet	B-NP	NNS	O	22	PMOD	-1
24	from	from	B-PP	IN	O	23	NMOD	-1
25	a	a	B-NP	DT	O	27	NMOD	-1
26	spontaneous	spontaneous	I-NP	JJ	O	27	NMOD	-1
27	model	model	I-NP	NN	O	34	NMOD	-1
28	of	of	B-PP	IN	O	27	NMOD	-1
29	type	type	B-NP	NN	O	31	NMOD	-1
30	2	2	I-NP	CD	O	31	NMOD	-1
31	diabetes	diabete	I-NP	NNS	O	28	PMOD	-1
32	,	,	O	,	O	34	P	-1
33	the	the	B-NP	DT	O	34	NMOD	-1
34	Goto-Kakizaki	Goto-Kakizaki	I-NP	NNP	O	24	PMOD	-1
35	(	(	O	(	O	37	DEP	-1
36	GK	GK	B-NP	NN	O	37	DEP	-1
37	)	)	O	)	O	34	NMOD	-1
38	rat	rat	B-NP	NN	O	34	NMOD	-1
39	.	.	O	.	O	11	P	-1

1	We	We	B-NP	PRP	O	3	SUB	-1
2	also	also	B-ADVP	RB	O	3	VMOD	-1
3	examined	examine	B-VP	VBD	O	0	ROOT	-1
4	islet	islet	B-NP	NN	B-DNA	12	NMOD	-1
5	endotheliuml/oxidative	endotheliuml/oxidative	I-NP	JJ	I-DNA	12	NMOD	-1
6	stress	stress	I-NP	NN	I-DNA	12	NMOD	-1
7	(	(	I-NP	(	I-DNA	12	NMOD	-1
8	OS	OS	I-NP	NN	I-DNA	12	NMOD	-1
9	)	)	I-NP	)	I-DNA	12	NMOD	-1
10	/inflammation-related	/inflammation-related	I-NP	JJ	I-DNA	12	NMOD	-1
11	gene	gene	I-NP	NN	I-DNA	12	NMOD	-1
12	expression	expression	I-NP	NN	O	17	NMOD	0
13	,	,	O	,	O	17	P	-1
14	islet	islet	B-NP	NN	O	15	NMOD	-1
15	vascularization	vascularization	I-NP	NN	O	17	NMOD	3	vascularization
16	and	and	O	CC	O	17	NMOD	-1
17	fibrosis	fibrosis	B-NP	NN	O	3	OBJ	-1
18	after	after	B-PP	IN	O	3	VMOD	-1
19	treatment	treatment	B-NP	NN	O	18	PMOD	19	treatment
20	with	with	B-PP	IN	O	19	NMOD	-1
21	the	the	B-NP	DT	O	27	NMOD	-1
22	interleukin-1	interleukin-1	I-NP	NN	B-protein	27	NMOD	-1
23	(	(	O	(	O	25	DEP	-1
24	IL-1	IL-1	B-NP	NN	B-protein	25	DEP	-1
25	)	)	O	)	O	22	NMOD	-1
26	receptor	receptor	B-NP	NN	O	27	NMOD	-1
27	antagonist	antagonist	I-NP	NN	O	20	PMOD	-1
28	(	(	O	(	O	30	DEP	-1
29	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	30	DEP	-1
30	)	)	O	)	O	27	NMOD	-1
31	.	.	O	.	O	3	P	-1

1	METHODOLOGY/PRINCIPAL	METHODOLOGY/PRINCIPAL	B-NP	NN	O	2	NMOD	-1
2	FINDINGS	FINDINGS	I-NP	NNS	O	6	SUB	-1
3	:	:	O	:	O	2	P	-1
4	Gene	Gene	B-NP	NN	O	5	NMOD	-1
5	expression	expression	I-NP	NN	O	6	SUB	0
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	analyzed	analyze	I-VP	VBN	O	6	VC	-1
8	by	by	B-PP	IN	O	7	VMOD	-1
9	quantitative	quantitative	B-NP	JJ	O	10	NMOD	-1
10	RT-PCR	RT-PCR	I-NP	NN	O	8	PMOD	-1
11	on	on	B-PP	IN	O	7	VMOD	-1
12	islets	islet	B-NP	NNS	O	11	PMOD	-1
13	isolated	isolate	B-VP	VBN	O	12	NMOD	19	isolated
14	from	from	B-PP	IN	O	13	VMOD	-1
15	10-week-old	10-week-old	B-NP	JJ	O	17	NMOD	-1
16	diabetic	diabetic	I-NP	JJ	O	17	NMOD	-1
17	GK	GK	I-NP	NN	O	21	NMOD	-1
18	and	and	I-NP	CC	O	21	NMOD	-1
19	control	control	I-NP	NN	O	21	NMOD	0
20	Wistar	Wistar	I-NP	NNP	O	21	NMOD	-1
21	rats	rat	I-NP	NNS	O	14	PMOD	-1
22	.	.	O	.	O	6	P	-1

1	Furthermore	Furthermore	B-ADVP	RB	O	5	VMOD	-1
2	,	,	O	,	O	5	P	-1
3	GK	GK	B-NP	NN	O	4	NMOD	-1
4	rats	rat	I-NP	NNS	O	5	SUB	-1
5	were	be	B-VP	VBD	O	0	ROOT	-1
6	treated	treat	I-VP	VBN	O	7	NMOD	19	treated
7	s.c	s.c	B-NP	NN	O	5	PRD	-1
8	twice	twice	B-ADVP	RB	O	7	NMOD	-1
9	daily	daily	I-ADVP	RB	O	8	AMOD	-1
10	with	with	B-PP	IN	O	7	NMOD	-1
11	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	10	PMOD	-1
12	(	(	O	(	O	7	NMOD	-1
13	Kineret	Kineret	B-NP	NNP	O	21	NMOD	-1
14	,	,	O	,	O	21	P	-1
15	Amgen	Amgen	B-NP	NNP	O	18	NMOD	-1
16	,	,	O	,	O	18	P	-1
17	100	100	B-NP	CD	O	18	NMOD	-1
18	mg/kg/day	mg/kg/day	I-NP	NN	O	21	NMOD	-1
19	)	)	O	)	O	18	NMOD	-1
20	or	or	O	CC	O	21	NMOD	-1
21	saline	saline	B-NP	NN	O	12	PMOD	-1
22	,	,	O	,	O	21	P	-1
23	from	from	B-PP	IN	O	21	NMOD	-1
24	4	4	B-NP	CD	O	25	NMOD	-1
25	weeks	week	I-NP	NNS	O	23	PMOD	-1
26	of	of	B-PP	IN	O	25	NMOD	-1
27	age	age	B-NP	NN	O	28	NMOD	-1
28	onwards	onward	I-NP	NNS	O	26	PMOD	-1
29	(	(	O	(	O	33	DEP	-1
30	onset	onset	B-NP	NN	O	33	DEP	-1
31	of	of	B-PP	IN	O	30	NMOD	-1
32	diabetes	diabetes	B-NP	NN	O	31	PMOD	-1
33	)	)	O	)	O	25	NMOD	-1
34	.	.	O	.	O	5	P	-1

1	Four	Four	B-NP	CD	O	2	NMOD	-1
2	weeks	week	I-NP	NNS	O	11	SUB	-1
3	later	later	B-ADVP	RB	O	11	VMOD	-1
4	,	,	O	,	O	11	P	-1
5	islet	islet	B-NP	NN	O	7	NMOD	-1
6	gene	gene	I-NP	NN	O	7	NMOD	-1
7	analysis	analysis	I-NP	NN	O	10	NMOD	-1
8	and	and	O	CC	O	10	NMOD	-1
9	pancreas	pancreas	B-NP	NN	O	10	NMOD	-1
10	immunochemistry	immunochemistry	I-NP	NN	O	11	SUB	-1
11	were	be	B-VP	VBD	O	0	ROOT	-1
12	performed	perform	I-VP	VBN	O	11	VC	-1
13	.	.	O	.	O	11	P	-1

1	Thirty-two	Thirty-two	B-NP	CD	O	2	NMOD	-1
2	genes	gene	I-NP	NNS	O	3	SUB	-1
3	were	be	B-VP	VBD	O	0	ROOT	-1
4	selected	select	I-VP	VBN	O	3	VC	-1
5	encoding	encode	B-VP	VBG	O	4	VMOD	-1
6	molecules	molecule	B-NP	NNS	O	5	OBJ	-1
7	involved	involve	B-VP	VBN	O	6	NMOD	0
8	in	in	B-PP	IN	O	7	VMOD	-1
9	endothelial	endothelial	B-NP	JJ	B-cell_type	11	NMOD	-1
10	cell	cell	I-NP	NN	I-cell_type	11	NMOD	-1
11	activation	activation	I-NP	NN	O	24	NMOD	17	activation
12	,	,	O	,	O	24	P	-1
13	particularly	particularly	B-NP	RB	O	14	NMOD	-1
14	fibrinolysis	fibrinolysis	I-NP	NN	O	24	NMOD	-1
15	,	,	O	,	O	24	P	-1
16	vascular	vascular	B-NP	JJ	O	17	NMOD	-1
17	tone	tone	I-NP	NN	O	24	NMOD	-1
18	,	,	O	,	O	24	P	-1
19	OS	OS	B-NP	NN	O	24	NMOD	-1
20	,	,	O	,	O	24	P	-1
21	angiogenesis	angiogenesis	B-NP	NN	O	24	NMOD	3	angiogenesis
22	and	and	O	CC	O	24	NMOD	-1
23	also	also	B-ADVP	RB	O	24	NMOD	-1
24	inflammation	inflammation	B-NP	NN	O	8	PMOD	-1
25	.	.	O	.	O	3	P	-1

1	All	All	B-NP	DT	O	2	NMOD	-1
2	genes	gene	I-NP	NNS	O	30	SUB	-1
3	except	except	B-PP	IN	O	2	NMOD	-1
4	those	those	B-NP	DT	O	3	PMOD	-1
5	encoding	encode	B-VP	VBG	O	4	NMOD	-1
6	angiotensinogen	angiotensinogen	B-NP	NN	O	9	NMOD	-1
7	and	and	I-NP	CC	O	9	NMOD	-1
8	epoxide	epoxide	I-NP	NN	B-protein	9	NMOD	-1
9	hydrolase	hydrolase	I-NP	NN	I-protein	22	NMOD	-1
10	(	(	O	(	O	9	NMOD	-1
11	that	that	B-NP	WDT	O	9	NMOD	-1
12	were	be	B-VP	VBD	O	11	SBAR	-1
13	decreased	decrease	I-VP	VBN	O	12	VC	18	decreased
14	)	)	O	)	O	13	VMOD	-1
15	,	,	O	,	O	9	P	-1
16	and	and	O	CC	O	17	NMOD	-1
17	12-lipoxygenase	12-lipoxygenase	B-NP	NN	B-protein	22	NMOD	-1
18	and	and	O	CC	O	22	NMOD	-1
19	vascular	vascular	B-NP	JJ	B-protein	22	NMOD	-1
20	endothelial	endothelial	I-NP	JJ	I-protein	22	NMOD	-1
21	growth	growth	I-NP	NN	I-protein	22	NMOD	0
22	factor	factor	I-NP	NN	I-protein	5	OBJ	-1
23	(	(	O	(	O	22	NMOD	-1
24	that	that	B-NP	WDT	O	22	NMOD	-1
25	showed	show	B-VP	VBD	O	24	SBAR	-1
26	no	no	B-NP	DT	O	27	NMOD	-1
27	change	change	I-NP	NN	O	25	OBJ	0
28	)	)	O	)	O	2	NMOD	-1
29	,	,	O	,	O	2	P	-1
30	were	be	B-VP	VBD	O	0	ROOT	-1
31	significantly	significantly	I-VP	RB	O	30	VMOD	-1
32	up-regulated	up-regulate	I-VP	VBN	O	30	VC	17	up-regulated
33	in	in	B-PP	IN	O	32	VMOD	-1
34	GK	GK	B-NP	NN	B-cell_type	35	NMOD	-1
35	islets	islet	I-NP	NNS	I-cell_type	33	PMOD	-1
36	.	.	O	.	O	30	P	-1

1	After	After	B-PP	IN	O	17	VMOD	-1
2	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	3	NMOD	-1
3	treatment	treatment	I-NP	NN	O	1	PMOD	19	treatment
4	of	of	B-PP	IN	O	3	NMOD	-1
5	GK	GK	B-NP	NN	O	6	NMOD	-1
6	rats	rat	I-NP	NNS	O	4	PMOD	-1
7	in	in	B-ADVP	FW	O	3	NMOD	-1
8	vivo	vivo	I-ADVP	FW	O	7	AMOD	-1
9	,	,	O	,	O	17	P	-1
10	most	most	B-NP	RBS	O	11	AMOD	-1
11	selected	select	I-NP	VBN	O	12	NMOD	-1
12	genes	gene	I-NP	NNS	O	17	SUB	-1
13	implied	imply	B-VP	VBN	O	12	NMOD	-1
14	in	in	B-PP	IN	O	13	VMOD	-1
15	endothelium/OS/immune	endothelium/OS/immune	B-NP	JJ	O	16	NMOD	-1
16	cells/fibrosis	cells/fibrosi	I-NP	NNS	O	14	PMOD	-1
17	were	be	B-VP	VBD	O	0	ROOT	-1
18	significantly	significantly	I-VP	RB	O	17	VMOD	-1
19	down-regulated	down-regulate	I-VP	VBN	O	17	VC	0
20	.	.	O	.	O	17	P	-1

1	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	3	SUB	-1
2	also	also	B-ADVP	RB	O	3	VMOD	-1
3	improved	improve	B-VP	VBD	O	0	ROOT	17	improved
4	islet	islet	B-NP	NN	O	5	NMOD	-1
5	vascularization	vascularization	I-NP	NN	O	3	OBJ	3	vascularization
6	,	,	O	,	O	3	P	-1
7	reduced	reduce	B-VP	VBD	O	3	VMOD	0
8	fibrosis	fibrosis	B-NP	NN	O	7	OBJ	-1
9	and	and	O	CC	O	7	VMOD	-1
10	ameliorated	ameliorate	B-NP	VBN	O	11	NMOD	-1
11	glycemia	glycemia	I-NP	NN	O	7	OBJ	-1
12	.	.	O	.	O	3	P	-1

1	CONCLUSIONS/SIGNIFICANCE	CONCLUSIONS/SIGNIFICANCE	B-NP	NN	O	5	NMOD	-1
2	:	:	O	:	O	1	P	-1
3	GK	GK	B-NP	NN	O	5	NMOD	-1
4	rat	rat	I-NP	NN	O	5	NMOD	-1
5	islets	islet	I-NP	NNS	O	6	SUB	-1
6	have	have	B-VP	VBP	O	0	ROOT	-1
7	increased	increase	I-VP	VBN	O	6	VC	0
8	mRNA	mRNA	B-NP	NN	B-RNA	9	NMOD	0
9	expression	expression	I-NP	NN	O	7	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	-1
11	markers	marker	B-NP	NNS	O	10	PMOD	-1
12	of	of	B-PP	IN	O	11	NMOD	-1
13	early	early	B-NP	JJ	O	17	NMOD	-1
14	islet	islet	I-NP	NN	O	17	NMOD	-1
15	endothelial	endothelial	I-NP	JJ	O	17	NMOD	-1
16	cell	cell	I-NP	NN	O	17	NMOD	-1
17	activation	activation	I-NP	NN	O	12	PMOD	17	activation
18	,	,	O	,	O	17	P	-1
19	possibly	possibly	B-VP	RB	O	20	VMOD	-1
20	triggered	trigger	I-VP	VBN	O	17	NMOD	0
21	by	by	B-PP	IN	O	20	VMOD	-1
22	several	several	B-NP	JJ	O	21	PMOD	-1
23	metabolic	metabolic	I-NP	JJ	B-protein	24	NMOD	-1
24	factors	factor	I-NP	NNS	I-protein	22	NMOD	-1
25	,	,	O	,	O	7	P	-1
26	and	and	O	CC	O	7	VMOD	-1
27	also	also	B-ADVP	RB	O	7	VMOD	-1
28	some	some	B-NP	DT	O	30	NMOD	-1
29	defense	defense	I-NP	NN	O	30	NMOD	0
30	mechanisms	mechanism	I-NP	NNS	O	7	VMOD	-1
31	.	.	O	.	O	6	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	beneficial	beneficial	I-NP	JJ	O	3	NMOD	-1
3	effect	effect	I-NP	NN	O	0	ROOT	0
4	of	of	B-PP	IN	O	3	NMOD	-1
5	IL-1Ra	IL-1Ra	B-NP	NN	B-protein	4	PMOD	-1
6	on	on	B-PP	IN	O	3	NMOD	-1
7	most	most	B-NP	JJS	O	11	NMOD	-1
8	islet	islet	I-NP	NN	O	11	NMOD	-1
9	endothelial/OS/immune	endothelial/OS/immune	I-NP	JJ	O	11	NMOD	-1
10	cells/fibrosis	cells/fibrosis	I-NP	NN	O	11	NMOD	-1
11	parameters	parameter	I-NP	NNS	O	6	PMOD	-1
12	analyzed	analyze	B-VP	VBN	O	11	NMOD	-1
13	highlights	highlight	B-NP	NNS	O	17	NMOD	-1
14	a	a	B-NP	DT	O	17	NMOD	-1
15	major	major	I-NP	JJ	O	17	NMOD	-1
16	endothelial-related	endothelial-related	I-NP	JJ	O	17	NMOD	-1
17	role	role	I-NP	NN	O	12	OBJ	16	role
18	for	for	B-PP	IN	O	17	NMOD	-1
19	IL-1	IL-1	B-NP	NN	B-protein	18	PMOD	-1
20	in	in	B-PP	IN	O	17	NMOD	-1
21	GK	GK	B-NP	NN	O	23	NMOD	-1
22	islet	islet	I-NP	NN	O	23	NMOD	-1
23	alterations	alteration	I-NP	NNS	O	20	PMOD	2	alterations
24	.	.	O	.	O	3	P	-1

1	Thus	Thus	B-ADVP	RB	O	6	VMOD	-1
2	,	,	O	,	O	6	P	-1
3	metabolically-altered	metabolically-altered	B-NP	JJ	O	5	NMOD	16	altered
4	islet	islet	I-NP	NN	O	5	NMOD	-1
5	endothelium	endothelium	I-NP	NN	O	6	SUB	-1
6	might	might	B-VP	MD	O	0	ROOT	-1
7	affect	affect	I-VP	VB	O	6	VC	16	affect
8	the	the	B-NP	DT	O	10	NMOD	-1
9	beta-cell	beta-cell	I-NP	NN	O	10	NMOD	-1
10	microenvironment	microenvironment	I-NP	NN	O	7	OBJ	-1
11	and	and	O	CC	O	7	VMOD	-1
12	contribute	contribute	B-VP	VBP	O	7	VMOD	0
13	to	to	B-PP	TO	O	12	VMOD	-1
14	progressive	progressive	B-NP	JJ	O	19	NMOD	-1
15	type	type	I-NP	NN	O	19	NMOD	-1
16	2	2	I-NP	CD	O	19	NMOD	-1
17	diabetic	diabetic	I-NP	JJ	O	19	NMOD	-1
18	beta-cell	beta-cell	I-NP	NN	O	19	NMOD	-1
19	dysfunction	dysfunction	I-NP	NN	O	13	PMOD	0
20	in	in	B-PP	IN	O	19	NMOD	-1
21	GK	GK	B-NP	NN	O	22	NMOD	-1
22	rats	rat	I-NP	NNS	O	20	PMOD	-1
23	.	.	O	.	O	6	P	-1

1	Counteracting	Counteract	B-VP	VBG	O	6	SUB	-1
2	islet	islet	B-NP	NN	O	5	NMOD	-1
3	endothelial	endothelial	I-NP	JJ	O	5	NMOD	-1
4	cell	cell	I-NP	NN	O	5	NMOD	-1
5	inflammation	inflammation	I-NP	NN	O	1	OBJ	-1
6	might	might	B-VP	MD	O	0	ROOT	-1
7	be	be	I-VP	VB	O	6	VC	-1
8	one	one	B-NP	CD	O	9	NMOD	-1
9	way	way	I-NP	NN	O	7	PRD	-1
10	to	to	B-VP	TO	O	11	VMOD	-1
11	ameliorate/prevent	ameliorate/prevent	I-VP	VB	O	9	NMOD	-1
12	beta-cell	beta-cell	B-NP	NN	O	13	NMOD	-1
13	dysfunction	dysfunction	I-NP	NN	O	11	OBJ	0
14	in	in	B-PP	IN	O	11	VMOD	-1
15	type	type	B-NP	NN	O	17	NMOD	-1
16	2	2	I-NP	CD	O	17	NMOD	-1
17	diabetes	diabete	I-NP	NNS	O	14	PMOD	-1
18	.	.	O	.	O	6	P	-1

